What it's for (Indications)
- Hydrocortisone and clotrimazole topical combination is primarily indicated for the treatment of inflammatory dermatoses where a superficial fungal infection (e.
- g.
- , candidiasis, dermatophytosis) is present or suspected.
- This includes conditions such as tinea corporis, tinea cruris, and tinea pedis that are accompanied by significant inflammatory symptoms like itching, redness, and irritation.
- The hydrocortisone component addresses the inflammation and associated pruritus, providing symptomatic relief, while clotrimazole targets the fungal pathogen.
- It is crucial to note that this medication is specifically formulated for superficial fungal infections with an inflammatory component and should not be used indiscriminately for all dermatoses or fungal infections without a clear indication of co-existing inflammation.
- Treatment duration should be limited to avoid prolonged corticosteroid exposure.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For adults and children over the age of 2 years, a thin layer of the hydrocortisone and clotrimazole cream should be applied to the affected skin area usually once or twice daily, as directed by a healthcare professional. The cream should be gently rubbed into the skin until it is evenly distributed. It is imperative to wash hands thoroughly before and after applying the medication to prevent contamination and self-inoculation. The duration of treatment typically does not exceed two weeks; however, it may vary based on the specific condition being treated and the clinical response. Continuous reassessment by a physician is recommended for prolonged use or if symptoms persist beyond the recommended treatment period. Occlusive dressings should generally be avoided unless specifically instructed by a physician, as they can increase systemic absorption of the corticosteroid component and the risk of adverse effects. |
Safety & Warnings
Common Side Effects
- Topical application of hydrocortisone and clotrimazole can lead to a range of side effects, primarily localized to the application site.
- Common adverse reactions attributed to the corticosteroid component (hydrocortisone) include burning, stinging, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, skin maceration, secondary infection, skin atrophy, striae, and miliaria.
- Systemic adverse effects such as hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria are rare with low-potency topical hydrocortisone but can occur, particularly with extensive or prolonged use, or under occlusive dressings.
- Side effects related to the clotrimazole component may include erythema, stinging, blistering, peeling, edema, pruritus, urticaria, and general irritation of the skin.
- Patients should report any persistent or worsening adverse reactions to their healthcare provider.
Serious Warnings
- Black Box Warning: This topical combination product, comprising hydrocortisone and clotrimazole, does not carry a formal FDA Black Box Warning. However, serious warnings are warranted due to the presence of a corticosteroid: **Serious Warnings: Risk of Systemic Corticosteroid Effects:** Although hydrocortisone is a low-potency corticosteroid, extensive, prolonged, or inappropriate use (e.g., on large surface areas, under occlusive dressings, or in pediatric patients) can lead to significant systemic absorption. This absorption may result in reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria. Pediatric patients are at an elevated risk of systemic toxicity due to a higher skin surface area-to-body mass ratio. Discontinue treatment if HPA axis suppression is suspected, and consider alternative non-corticosteroid therapies. **Potential for Misdiagnosis and Worsening Conditions:** The corticosteroid component can mask the clinical signs of underlying skin infections or other dermatological conditions, delaying appropriate diagnosis and treatment. Use without a confirmed fungal diagnosis or for prolonged periods can lead to antifungal resistance or exacerbation of non-fungal conditions (e.g., bacterial or viral infections, rosacea, acne). Re-evaluate the patient's condition if no improvement is seen within 1-2 weeks, or if symptoms worsen, to confirm the diagnosis and adjust treatment accordingly. **Local Adverse Reactions:** Prolonged application, particularly on sensitive areas such as the face, groin, or axillae, and in children, significantly increases the risk of local adverse reactions including skin atrophy, striae, telangiectasias, and perioral dermatitis. These effects can be disfiguring and potentially irreversible. Limit the duration of therapy to the shortest period necessary to achieve therapeutic efficacy.
- This combination product is for external use only and should not be used for ophthalmic, oral, or intravaginal application.
- Avoid contact with eyes, mouth, and other mucous membranes.
- Prolonged or extensive application, especially on large body surfaces, under occlusion, in intertriginous areas, or on the face, significantly increases the risk of systemic corticosteroid absorption, potentially leading to HPA axis suppression, Cushing's syndrome, hyperglycemia, and growth retardation in children.
- Pediatric patients are particularly susceptible due to their higher skin surface area-to-body weight ratio.
- The corticosteroid component can mask the symptoms of underlying infections or cause exacerbation if the infection is not primarily fungal.
- Discontinue use if irritation, sensitization, or superinfection develops.
- Re-evaluate the diagnosis if no improvement is observed after the recommended treatment duration (typically 1-2 weeks).
- Pregnancy and lactation: use with caution and only if the potential benefit justifies the potential risk to the fetus or infant; consultation with a healthcare professional is essential.
How it Works (Mechanism of Action)
Hydrocortisone and clotrimazole exert their therapeutic effects through distinct yet complementary mechanisms. Hydrocortisone, a low-potency corticosteroid, acts as an anti-inflammatory, antipruritic, and vasoconstrictive agent. Its anti-inflammatory action is mediated by the induction of phospholipase A2 inhibitory proteins, called lipocortins. These proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. This effectively reduces the signs and symptoms of inflammation, including redness, swelling, and itching. Clotrimazole, an azole antifungal, exerts its fungicidal or fungistatic activity by inhibiting the biosynthesis of ergosterol, which is a vital component of fungal cell membranes. This inhibition leads to structural and functional damage to the fungal cell membrane, resulting in altered membrane permeability, leakage of essential intracellular components, and ultimately fungal cell death. The combination thus provides both symptomatic relief from inflammation and targets the underlying fungal infection.